Fully Online Care
In-House RxDose Adjustments By Provider
Prescription IncludedYes
Telehealth IncludedYes
Online-Only OptionYes
Skip LabsUnless Requested
- Flat-rate pricing · All-inclusive pricing
- No commitment required · Manual refills · Cancel anytime
- 100% online · Free consultation
- Third-party tested
- Free expedited shipping · Supplies included · Discreet packaging
- Strong customer reviews
- Tirzepatide, Semaglutide
- Available in all 50 states
- Video consultation required
- No additive-free options
- No verified LegitScript certification
Provider Plans
Monthly Supply Plan
TirzepatideMonthly
$197/avg
PharmacyStrive (503A)
Third-Party Tested
AdditivesGlycine
Cyanocobalamin (B12)
PreservativeBenzyl Alcohol
BUD (Shelf Life)90 Days
Based On 503A
BillingPaid Upfront
CommitmentNo Commitment
Other FeesNo Extra Fees
Auto-RenewsNo
| DoseYour Supply | Your Price | Your Supply | Avg/mo | Your Value |
|---|---|---|---|---|
| 2.5mg/wk10mg/mo | $197.00 | 10mg | 197 | $19.70/mg |
| 5.0mg/wk20mg/mo | $197.00 | 20mg | 197 | $9.85/mg |
| 7.5mg/wk30mg/mo | $197.00 | 30mg | 197 | $6.57/mg |
| 10.0mg/wk40mg/mo | $197.00 | 40mg | 197 | $4.92/mg |
| 12.5mg/wk50mg/mo | $197.00 | 50mg | 197 | $3.94/mg |
| 15.0mg/wk60mg/mo | $197.00 | 60mg | 197 | $3.28/mg |
States Excluded From PlanNone
Provider Details
Self-Pay · HSA / FSA Eligible
CreditCareCredit
Insurance AcceptedNo
HSA/FSA AcceptedYes
Financing AvailableYes
Trust
Strong Customer Reviews100,000+ Patients
LegitScript CertifiedNot Disclosed
HIPAA CompliantYes
Free Express Shipping
Supplies IncludedCold-Packed
Free ShippingYes
Expedited ShippingYes
Discreet PackagingYes
Tirz + Sema · 503A
Format: Injection
Offers TirzepatideYes
Offers SemaglutideYes
Offers BrandNo
Other TreatmentsYes
Contact & Support
Live ChatMobile App8 AM-5 PM EST
Emailsupport@liferx.md
Phone(609) 201-0119
Address401 Cooper Landing Rd # C1, Cherry Hill, NJ 08002
Websitehttps://liferx.md
Provider Notes
Compliance
The FDA resolved the semaglutide shortage on April 22, 2025. Compounding is permitted only for individually identified patients when a prescribing practitioner determines that the compounded preparation produces a significant difference for their patient compared to the FDA-approved product.